Arcutis Biotherapeutics up after Q1 revenue rises

Arcutis Biotherapeutics

14/05/2024 22:07

** Drugmaker Arcutis Biotherapeutics'  ARQT.O  shares rise
16.9% to $9.50 after market
    ** Company posts Q1 revenue of $49.6 mln vs $2.8 mln a year
earlier
    ** Company posts Q1 net product revenue of $21.6 mln from
its psoriasis and eczema treatment cream Zoryve vs $2.8 mln a
year earlier
    ** Arcutis records $28 mln in revenue from upfront and
milestone payments in Q1
    ** Company posts Q1 net loss of $35.4 mln vs loss of $80.1
mln a year earlier
    ** Stock has more than doubled YTD

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com))